China
Africa
Explore chapters and articles related to this topic
Endocrine Disorders, Contraception, and Hormone Therapy during Pregnancy
Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022
Pergonal is an extract of urine from postmenopausal women; it contains follicle-stimulating hormone (FSH) and luteinizing hormone (LH). It is administered by intramuscular injection and is used to stimulate multiple ovarian follicular development in ovulation induction cycles. Metrodin is a purified extract of urine from postmenopausal women and primarily contains FSH. It is similar to Pergonal in its administration protocols. The frequency of birth defects was not increased among 176 and 168 infants born following exposure to follitropin compounds, alpha and beta, respectively, in the Swedish Birth Defects Registry (Kallen, 2019). Among 54 infants exposed to urofollitropin, the frequency of congenital anomalies was not increased (Kallen, 2019). In total, 398 infants were born after FSH treatments, and the frequency of malformations was not increased (Kallen, 2019).
Genetic analysis of embryo in a human case of spontaneous oocyte activation: a case report
Published in Gynecological Endocrinology, 2020
Yuanyuan Ye, Na Li, Xiaohong Yan, Rongfeng Wu, Weidong Zhou, Ling Cheng, Youzhu Li
After a discussion with the patient, a decision was made to perform a short-term in-vitro fertilization (IVF) cycle. She underwent a mild ovarian stimulation and gonadotropin-releasing hormone-antagonist (GnRH-antagonist) protocol. The ovarian stimulation was initiated with urofollitropin for rejection (Livzon, China) in a dose of 150 IU im combined with GH 2.5 IU s.c. per day for 5 days, starting on day 6 of the menstrual cycle. On the sixth day of stimulation (day 11 of the menstrual cycle), urofollitropin for rejection was decreased to 75 IU and cetrorelix (Merck Serono, Switzerland) was added in a dose of 0.25 mg s.c. combined with HMG 75 IU im per day for 4 days. Daily monitoring of follicular development by transvaginal ultrasound tests and serum E2 measurements were required. Ovulation was triggered by injecting subcutaneously 10,000 IU of HCG (Livzon, China) when three leading follicles reached 18 mm, with serum E2 968 pg/ml. Transvaginal ultrasound-guided oocyte retrieval was performed approximately 37 h after HCG injection and completed without complications.
Arterial stiffness during controlled ovarian hyperstimulation and early pregnancy in women exposed to assisted reproduction
Published in Hypertension in Pregnancy, 2018
Emma von Wowern, Pia Saldeen, Per Olofsson
For ovarian stimulation, gonadotrophins were given, either as follitropin alfa (GONAL-f®, Merck Sharp & Dohme AB, Stockholm, Sweden; Bemfola®, Gedeon Richter Plc, Budapest, Hungary), follitropin beta (Puregon®, Merck Sharp & Dohme AB, Stockholm, Sweden), menotropin (Menopur®, Ferring Läkemedel AB, Malmö, Sweden), or urofollitropin (Fostimon®, HB Medical ApS, Hörsholm, Denmark). The follicular growth was followed by serial transvaginal ultrasound scans and oocyte maturation was induced with recombinant hCG (Ovitrelle®, 250 μg, Merck Sharp & Dohme AB, Stockholm, Sweden) when the mean diameters of leading follicles were 18–20 mm. Oocyte retrieval was then scheduled 36 h after the hCG injection. Oocyte retrieval was performed transvaginally under ultrasound guidance in conscious sedation with fentanyl 1 μg/kg IV (Fentanyl®,50 μg/mL, B. Braun Medical AB, Danderyd, Sweden). Propofol 20–40 mg IV (Propofol-®Lipuro, B. Braun Medical AB, Danderyd, Sweden) was given when needed. Embryos were cultured in SAGE 1-StepTM medium (ORIGIO a/s, Måløv, Denmark). Embryo transfer was performed with a Cook Sydney IVF embryo transfer catheter set (Cook Medical, Bloomington, Indiana, USA).
Nurse evaluation of the redesigned fertility pen injector: a questionnaire-based observational survey
Published in Expert Opinion on Drug Delivery, 2018
The nurses saw a mean of 100 patients per month, and 20 (67%) taught more than 16 patients per month on the use of self-injection devices. All of the nurses had taught patients to use the previous version of the pen injector, and the majority of nurses had also taught patients to inject Menopur® (menotropin; Ferring Pharmaceuticals Ltd, West Drayton, UK) and to use the Puregon® (follitropin beta; Merck Sharp & Dohme, Hoddesdon, UK) pen injector (24 [80%] and 21 [70%], respectively; Table 2). This experience was reflected in the nurses’ rating of familiarity with pen injectors: nurses were most familiar with the previous GONAL-f and Puregon pen injectors and least familiar with the Ovaleap® (follitropin alfa; Teva Pharma B.V., Harlow, UK] pen injector and with use of Bravelle® (urofollitropin; Ferring Pharmaceuticals Ltd, West Drayton, UK). None of the nurses required the full time allotted for training in the use the pen.